Catheter Precision (VTAK) AI Stock Analysis

• Market Cap: $2.50M
• Dividend Yield: N/A
• Average Volume (3M): 176.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: -4.98%
• EPS Growth: 95.05%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 60
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 9,268,632
• 10 Day Avg. Volume: 384,846
• 30 Day Avg. Volume: 176,094
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 4.50
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 27.32
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

VTAK's overall stock score reflects significant challenges in financial performance, particularly in achieving profitability and generating positive cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages. Valuation remains unattractive due to ongoing losses and a negative P/E ratio. While the corporate event of an executive stock option plan is positive, it does not materially improve the current financial and technical outlook.

Catheter Precision Business Overview & Revenue Model

Company Description

Catheter Precision (VTAK) is a medical technology company that specializes in the development and commercialization of innovative catheter-based devices for the diagnosis and treatment of cardiac arrhythmias. The company operates within the medical device sector, focusing on electrophysiology and interventional cardiology. Its core products include advanced catheter systems designed to improve the accuracy and effectiveness of cardiac procedures, thereby enhancing patient outcomes and procedural efficiency.

How the Company Makes Money

Catheter Precision generates revenue primarily through the sale of its catheter-based medical devices to hospitals, clinics, and healthcare providers. The company may also engage in strategic partnerships with larger medical device firms to expand its market reach and distribution capabilities. Additionally, revenue streams could include licensing agreements for its proprietary technology and intellectual property, as well as potential service agreements for training and support related to the use of its products. The company’s earnings are influenced by factors such as the adoption rate of its technologies in healthcare facilities, the development of new products, and its ability to navigate regulatory approvals in various markets.

Catheter Precision Financial Statement Overview

Summary

VTAK's financial performance is concerning, with significant challenges in achieving profitability and positive cash flows. The income statement reflects a decline in revenue and persistent operational losses. While the balance sheet shows some stability with a manageable debt-to-equity ratio, negative return on equity due to ongoing losses is a concern. The cash flow statement highlights the need for improved operational efficiency as cash outflows exceed inflows.

Income Statement

The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.

Balance Sheet

The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.

Cash Flow

Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
442.00K	14.00K	22.00K	4.41M	7.20M
	Gross Profit
412.00K	-147.00K	-1.54M	-1.08M	-1.65M
	EBIT
-78.12M	-26.96M	-29.27M	-36.06M	-57.73M
	EBITDA
-15.11M	-22.37M	-27.70M	-33.30M	-54.94M
	Net Income Common Stockholders
-70.57M	-26.86M	-25.07M	-36.05M	-56.96M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.56M	15.86M	15.04M	23.91M	30.58M
	Total Assets
30.74M	16.84M	21.04M	33.44M	44.08M
	Total Debt
372.00K	124.17K	2.26M	4.88M	3.50M
	Net Debt
-3.19M	-15.73M	-12.78M	-19.02M	-11.09M
	Total Liabilities
9.54M	7.58M	7.37M	12.29M	10.93M
	Stockholders Equity
21.19M	9.26M	13.67M	21.15M	33.15M
Cash Flow		Free Cash Flow
-20.70M	-22.59M	-27.89M	-28.37M	-33.44M
	Operating Cash Flow
-20.62M	-22.57M	-27.63M	-28.30M	-33.17M
	Investing Cash Flow
-61.00K	21.00K	3.80M	15.93M	-16.03M
	Financing Cash Flow
8.39M	23.36M	14.96M	21.69M	-526.00K

Catheter Precision Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.34, and below the 200-day MA of 0.64, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.79 is Neutral, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTAK.

Catheter Precision Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.35B	3.83	-41.61%	2.85%	17.10%	1.22%
NUWE	47 Neutral	$4.64M	―	-229.24%	―	-1.40%	91.79%
VVOS	46 Neutral	$16.08M	―	-266.25%	―	8.91%	70.18%
SINT	42 Neutral	$6.97M	―	-174.07%	―	9.90%	94.56%
HSCS	41 Neutral	$3.89M	―	-163.47%	―	-100.00%	78.91%
VTAK	39 Underperform	$2.50M	―	-101.02%	―	-4.98%	95.05%
RSLS	37 Underperform	$4.74M	―	-222.46%	―	-7.74%	93.25%

Catheter Precision Corporate Events

Catheter Precision Approves Executive Stock Option Plan

On January 29, 2025, Catheter Precision, Inc.’s Board of Directors approved incentive stock options for executives as part of the 2023 Executive Incentive Plan. David Jenkins, CEO, received options for 450,000 shares, while Marie-Claude Jacques, Chief Commercial Officer, was granted options for 250,000 shares, with vesting tied to time and sales targets. This move aims to align the executives’ interests with company performance and enhance stakeholder value.